What is HC Wainwright’s Estimate for CRSP FY2024 Earnings?

CRISPR Therapeutics AG (NASDAQ:CRSP) – Analysts at HC Wainwright issued their FY2024 earnings per share estimates for shares of CRISPR Therapeutics in a research note issued to investors on Monday, February 3rd. HC Wainwright analyst M. Kapoor expects that the company will post earnings per share of ($4.83) for the year. HC Wainwright currently has a “Buy” rating and a $65.00 price target on the stock. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.10) per share. HC Wainwright also issued estimates for CRISPR Therapeutics’ Q4 2024 earnings at ($0.98) EPS, Q1 2025 earnings at ($1.11) EPS, Q2 2025 earnings at ($1.01) EPS, Q3 2025 earnings at ($1.11) EPS, Q4 2025 earnings at ($1.03) EPS and FY2025 earnings at ($4.25) EPS.

A number of other research analysts also recently weighed in on CRSP. Bank of America lowered their price target on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research note on Monday, December 30th. JMP Securities reissued a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a research report on Friday, December 20th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Finally, Barclays cut their target price on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $77.59.

CRISPR Therapeutics Stock Performance

CRISPR Therapeutics stock opened at $40.61 on Wednesday. CRISPR Therapeutics has a 52 week low of $36.52 and a 52 week high of $91.10. The firm has a market capitalization of $3.47 billion, a price-to-earnings ratio of -14.35 and a beta of 1.67. The company has a 50 day moving average price of $43.20 and a 200 day moving average price of $46.82.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.41. The business had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same period last year, the firm posted ($1.41) earnings per share.

Insider Activity

In related news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the completion of the transaction, the chief executive officer now owns 181,540 shares of the company’s stock, valued at approximately $10,002,854. The trade was a 7.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Bank of Montreal Can raised its stake in CRISPR Therapeutics by 26.3% during the 2nd quarter. Bank of Montreal Can now owns 7,556 shares of the company’s stock valued at $408,000 after purchasing an additional 1,574 shares during the last quarter. Creative Planning raised its position in shares of CRISPR Therapeutics by 3.2% during the second quarter. Creative Planning now owns 14,750 shares of the company’s stock valued at $797,000 after buying an additional 456 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in shares of CRISPR Therapeutics by 4.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,606 shares of the company’s stock valued at $249,000 after buying an additional 211 shares during the period. Sanctuary Advisors LLC acquired a new stake in CRISPR Therapeutics during the second quarter worth about $381,000. Finally, Exchange Traded Concepts LLC increased its stake in CRISPR Therapeutics by 22.8% during the third quarter. Exchange Traded Concepts LLC now owns 19,192 shares of the company’s stock valued at $902,000 after acquiring an additional 3,563 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.